Systemic and organ-specific anti-inflammatory effects of sodium-glucose cotransporter-2 inhibitors
Copyright © 2024 Elsevier Ltd. All rights reserved..
Inflammation plays an essential role and is a common feature in the pathogenesis of many chronic diseases. The exact mechanisms through which sodium-glucose cotransporter-2 (SGLT2) inhibitors achieve their much-acclaimed clinical benefits largely remain unknown. In this review, we detail the systemic and tissue- or organ-specific anti-inflammatory effects of SGLT2 inhibitors using evidence from animal and human studies. We discuss the potential pathways through which SGLT2 inhibitors exert their anti-inflammatory effects, including oxidative stress, mitochondrial, and inflammasome pathways. Finally, we highlight the need for further investigation of the extent of the contribution of the anti-inflammatory effects of SGLT2 inhibition to improvements in cardiometabolic and renal outcomes in clinical studies.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Trends in endocrinology and metabolism: TEM - (2024) vom: 29. Feb. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Mashayekhi, Mona [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Cytokines |
|---|
| Anmerkungen: |
Date Revised 29.02.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1016/j.tem.2024.02.003 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369137906 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369137906 | ||
| 003 | DE-627 | ||
| 005 | 20240301233234.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240301s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.tem.2024.02.003 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1313.xml |
| 035 | |a (DE-627)NLM369137906 | ||
| 035 | |a (NLM)38423898 | ||
| 035 | |a (PII)S1043-2760(24)00032-8 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Mashayekhi, Mona |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Systemic and organ-specific anti-inflammatory effects of sodium-glucose cotransporter-2 inhibitors |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 29.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Copyright © 2024 Elsevier Ltd. All rights reserved. | ||
| 520 | |a Inflammation plays an essential role and is a common feature in the pathogenesis of many chronic diseases. The exact mechanisms through which sodium-glucose cotransporter-2 (SGLT2) inhibitors achieve their much-acclaimed clinical benefits largely remain unknown. In this review, we detail the systemic and tissue- or organ-specific anti-inflammatory effects of SGLT2 inhibitors using evidence from animal and human studies. We discuss the potential pathways through which SGLT2 inhibitors exert their anti-inflammatory effects, including oxidative stress, mitochondrial, and inflammasome pathways. Finally, we highlight the need for further investigation of the extent of the contribution of the anti-inflammatory effects of SGLT2 inhibition to improvements in cardiometabolic and renal outcomes in clinical studies | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a SGLT2 inhibition | |
| 650 | 4 | |a cytokines | |
| 650 | 4 | |a inflammation | |
| 650 | 4 | |a macrophages | |
| 650 | 4 | |a monocytes | |
| 650 | 4 | |a sodium-glucose cotransporter-2 (SGLT2) | |
| 700 | 1 | |a Safa, Bilgunay Ilkin |e verfasserin |4 aut | |
| 700 | 1 | |a Gonzalez, Matthew S C |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Sangwon F |e verfasserin |4 aut | |
| 700 | 1 | |a Echouffo-Tcheugui, Justin B |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Trends in endocrinology and metabolism: TEM |d 1989 |g (2024) vom: 29. Feb. |w (DE-627)NLM102549273 |x 1879-3061 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:29 |g month:02 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.tem.2024.02.003 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 29 |c 02 | ||